Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: Preclinical and clinical data

CNS Drug Reviews

Volumn 12, Issue 2, 2006, Pages 91-99

  Carai, Mauro A M ^a,b   Colombo, Giancarlo ^a   Maccioni, Paola ^a   Gessa, Gian Luigi ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

Body weight; Cannabinoids; CB1 receptor antagonists; Food Intake; Obesity; Overweight; Rimonabant; SR141716A

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; RIMONABANT; UNCLASSIFIED DRUG;

ANXIETY DISORDER; ARTHRALGIA; BACKACHE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOOD INTAKE; HEADACHE; HUMAN; INFECTION; INFLUENZA; INSOMNIA; METABOLISM; NAUSEA; NONHUMAN; OBESITY; REVIEW; RHINOPHARYNGITIS; WEIGHT CONTROL; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; DRUG EVALUATION, PRECLINICAL; EATING; HUMANS; PHARMACOLOGY, CLINICAL; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 33748078481     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2006.00091.x     Document Type: Review

References (52)

1. th Annual Conference of SRNT Europe; Tübingen, Germany, 2004:35.
2. 1) receptors. Psychopharmacology 1997;132:104-106.
3. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914.
4. Carai MAM, Colombo G, Gessa GL. Rimonabant: The first therapeutically relevant cannabinoid antagonist. Life Sci 2005;77:2339-2350.
5. Chambers AP, Sharkey KA, Koopmans HS. Cannabinoid (CB)1 receptor antagonist, AM251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 2004;82:863-869.
6. 1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998;135:324-332.
7. Chen RZ, Huang RR, Shen CP, et al. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res 2004;999:227-230.
8. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998;63:PLH3-PL117.
9. Colombo G, Serra S, Vacca G, et al. Endocannabinoid system and alcohol addiction: Pharmacological studies. Pharmacol Biochem Behav 2005;81:369-380.
10. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
11. De Vry J, Schreiber R, Eckel G, et al. Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur J Pharmacol 2004;483: 55-63.
12. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
13. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8: 585-589.
14. Foltin RW, Brady JV, Fischman MW. Behavioral analysis of marijuana effects of food intake in humans. Pharmacol Biochem Behav 1986;25:577-582.
15. Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988;11:1-14.
16. Freedland CS, Posten JS, Porrino LJ. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 2000;67:265-270.
17. 1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Exp Opin Invest Drugs 2006;15: 307-315.
18. Gessa GL, Orrù A, Lai P, et al. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology 2006;185:248-254.
19. 1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-9617.
20. Hajnal A, Norgren R. Accumbens dopamine mechanisms in sucrose intake. Brain Res 2001;904:76-84.
21. Halikas JA, Goodwin DW, Guze SB. Marijuana effects. A survey of regular users. JAMA 1971;217: 692-694.
22. Harrold JA, Elliott JC, King PJ, et al. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: A role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002;952:232-238.
23. Harrold JA, Williams G The cannabinoid system: A role in both the homeostatic and hedonic control of eating? Br J Nutrition 2003;90:729-734.
24. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol Ther 2006; In press.
25. 9- tetrahydrocarmabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology 2003;165:370-377.
26. 1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003;462:125-132.
27. 1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003;84:698-704.
28. 1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19: 1567-1569.
29. Kirkham TC, Williams CM, Fezza F, et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136:550-557.
30. 1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obesity 2005;29: 183-187.
31. Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: A microdialysis study. Pharmacol Biochem Behav 1996;53:221-226.
32. 1 antagonists SR141716A and AM251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003;14: 583-588.
33. Milano WC, Wild KD, Hui YZ, et al. PCP, THC, ethanol, and morphine and consumption of palatable solutions. Pharmacol Biochem Behav 1988;31:893-897.
34. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006;295:761-775.
35. Poirier B, Bidouard JP, Cadrouvele C, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7:65-72.
36. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995;92:12304-12308.
37. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-R353.
38. 1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640-648.
39. Rinaldi-Carmona M, Barth F, Héauim M, et al. SR141716A, a potent and selective antagonist of the cannabinoid receptor. FEBS Lett 1994;350:240-244.
40. 1 cannabinoid receptor. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004;310: 905-914.
41. Rowland NE, Mukherjee M, Robertson K. Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 2001; 159:111-116.
42. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22:565-572.
43. 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998;9:179-181.
44. Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 2005;30: 2035-2045.
45. 1 opioid receptor mechanism. Science 1997;276:2048-2050.
46. Tart CT. Marijuana intoxication: Common experiences. Nature 1970;226:701-704.
47. Tonstad S. Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2006;16:156-162.
48. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397.
49. Verty AN, McGregor IS, Mallet PE. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004;354: 217-220.
50. 1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 2003;167:103-111.
51. Vickers SP, Kennett GA. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 2005;6: 215-223.
52. 1) receptors. Psychopharmacology 1999;143:315-317.